Do Systemic Alpha-2 Agonists Lower Glaucoma Risk?

A large US cohort study found systemic alpha-2 agonist use was associated with a lower hazard of glaucoma-related diagnoses vs. beta-blockers.

Category	Detail
Condition	Glaucoma-related diagnoses
Key Mechanisms	Intraocular pressure modulation and vascular-neuroprotective pathways
Target Population	Adult patients with hypertension aged 40 years or older
Care Setting	Multicenter, retrospective cohort study using electronic health records

Systemic alpha-2 agonists associated with lower odds of ocular hypertension and primary open-angle glaucoma compared to beta-blockers.
2% of alpha-2 agonist users developed primary open-angle glaucoma at 3 years vs. 3% of beta-blocker users.
At 5 years, 2% of alpha-2 agonist users vs. 4% of beta-blocker users developed primary open-angle glaucoma.
Ocular hypertension rates were lower among alpha-2 agonist users at 5 years (2% vs. 4%).
Findings warrant further prospective and mechanistic study.

Diagnoses based on diagnostic codes; further detailed ophthalmic measures not included.

Consider systemic alpha-2 agonists for hypertension management in patients at risk for glaucoma.

Monitor for glaucoma-related diagnoses in patients receiving systemic alpha-2 agonists.

Observational study design limits causality; potential for residual confounding.

Patients aged 40 years or older with hypertension

Systemic alpha-2 agonists may lower glaucoma risk compared to beta-blockers.

Further exploration of the association between systemic alpha-2 agonists and glaucoma risk is recommended.

Clinical Scorecard: Do Systemic Alpha-2 Agonists Lower Glaucoma Risk?